Background Degenerative diseases become prominent with progressive ageing and thus present the most urgent biomedical challenge facing developed countries to date. One of the most prevalent musculoskeletal diseases caused during aging ...

Background Cystic Fibrosis (CF) is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. There is no known cure for cystic fibrosis and the average life expectancy is between 42 and 50 years ...

  Highlights: CBD is a highly lipophilic molecule   and therefore the preparation of cannabinoid-containing non- alcoholic beverages requires in general the use of various and important concentrations of additives.  We found a new technology ...

Background The most common type of cannabinoids is tetrahydrocannabinol (THC) which ensures a psychedelic high but also helps in relieving chronic pain and stimulates poor appetite. On the other hand, cannabidiol (CBD) as well as CBG and CBC ...

Background Bacteria communicate and coordinate population behavior through the mechanism of quorum sensing (QS), which controls the expression of genes that affect a variety of bacterial processes. Cannabis, Cannabinoids and endo-cannabinoids ...

Keywords Innovative carrier, Nasal administration, Delivery to brain, Treatment of pain, disorders in Parkinson's disease, Multiple Sclerosis, Alzheimer, Epilepsy and brain trauma Current development stage Tested in animal model for ...

Background  Micro-emulsions are formed more or less spontaneously when their components are brought into contact.  They have been the only successful delivery systems for certain types of pharmaceutical compounds, particularly compounds such as ...

  Categories Cannabinoids, Drug Delivery, Novel Carrier, Oral Formulation Development Stage In-vivo proof of concept Patent Status PCT patent application filed Market Improved delivery of cannabinoids is a real need and has an increasing ...

  Categories Cannabinoid Administration, Formulation, Drug Delivery, Novel Carriers, Transdermal Formulation, Nasal Formulation, Oral formulation Development Stage In-vivo proof of concept Patent Status Several patent applications – new ...

Oral Dosage Form for Immediate and Prolonged Action of Cannabinoids     Categories  Cannabinoids, Drug Delivery, Novel Carrier, Oral Formulation Development Stage In-vivo proof of concept Patent Status PCT patent application filed Market ...

Prof. Yaron Ilan, Department of Human Nutrition and Metabolism and Liver Unit Hadassah Hospital Background To date, there is no effective treatment of liver diseases with the related Hepatic-Encephalopathy symptoms. It is established that ...

Background Agonists that bind well to the cannabinoid CB2 receptor and do not bind, or only bind weakly to the cannabinoid CB1 receptor are very promising therapeutic compounds for a wide range of disorders. CB1 agonists (such as the ...